Johnson & Johnson (JNJ)
| Previous Close | 144.59 |
| Open | 148.74 |
| Bid | 150.93 x 900 |
| Ask | 151.00 x 900 |
| Day's Range | 147.62 - 151.40 |
| 52 Week Range | 143.13 - 175.97 |
| Volume | |
| Avg. Volume | 7,644,877 |
| Market Cap | 364.262B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 20.34 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.96 (3.43%) |
| Ex-Dividend Date | May 20, 2024 |
| 1y Target Est | N/A |
- Bloomberg
J&J Seeks Backing for $11 Billion Baby Powder Cancer Deal
(Bloomberg) -- Johnson & Johnson will ask thousands of people suing over its allegedly tainted baby powder to vote for a settlement that would resolve all litigation for $11 billion — $2.1 billion more than the company offered last year.Most Read from BloombergTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests Over 300 Protesters in Crackdown on College CampusesFed to Signal Delay of Interest-Rate CutsThe Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Econo
- CNN Business
Johnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuits
Johnson & Johnson is moving forward with a proposed settlement of tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer.
- Reuters
UPDATE 1-J&J advances $6.48 billion settlement of talc cancer lawsuits
Johnson & Johnson said on Wednesday it is moving forward with a $6.48 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer. The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims.
